#United States #Phoenix #BioLab Holdings #Imbed Biosciences #Microlyte

BioLab Holdings Expands Its Horizon with Strategic Investment

In a significant move to improve wound care technology, BioLab Holdings, Inc., a Phoenix-based medical manufacturing leader, has declared a strategic investment in Imbed Biosciences, Inc.. This Wisconsin-based company is renowned for its pioneering work in fully-synthetic antimicrobial solutions, particularly the SAM™ Antimicrobial Technology and Microlyte®, a wound matrix derived from it. This partnership is set to revolutionize how skin substitutes are offered in medical settings, especially physician offices, by aligning with diverse clinical needs across wound management.

Advancing Wound Care Solutions

The inclusion of Microlyte® into BioLab's product portfolio is especially pivotal. This antimicrobial wound matrix is crafted from bioresorbable polymers designed to adapt swiftly to the unique contours of a wound, significantly reducing microbial presence and fostering tissue regeneration. Whether dealing with chronic, acute, traumatic, or surgical wounds, Microlyte® guarantees at least 72 hours of sustained, silver-based antimicrobial action while maintaining an optimal moist environment for healing. It has been scientifically engineered to create a favorable matrix surface tension that promotes vital processes like cell migration and proliferation.

Clinical Benefits and Innovations

Early clinical evaluations of Microlyte® have demonstrated impressive results, showcasing accelerated wound area reduction and high closure rates for chronic, non-healing wounds within 12 weeks. The synthetic nature of Microlyte® mitigates common supply chain and variability issues typically associated with biological matrices, presenting a consistent and user-friendly choice for clinical professionals.

Jaime Leija, President of BioLab, stated, “Imbed Biosciences has developed one of the most advanced synthetic platforms seen in wound care. This partnership enhances the resources available to clinicians, especially for managing complex wounds without adding to operational strain.”

A Unified Approach to Wound Management

Imbed's CEO, Terry Bromley, echoed these sentiments, emphasizing their commitment to developing solutions that complement natural healing. He noted, “BioLab's established clinical presence and dedication to evidence-based practices make them an ideal collaborator as we aim for broader adoption of Microlyte® across the nation.” Together, the companies are set to redefine standards for accessibility and performance in the antimicrobial wound care landscape.

Plans for Future Development

The strategic investment will not only accelerate the commercialization efforts of Imbed within the United States but also expand distribution networks and back the continued development of next-generation matrices based on SAM™ technology. Additionally, there are intentions to create platforms that combine pain management agents and other therapeutic components. Both companies are dedicated to collaborating closely with healthcare professionals to ensure a seamless deployment of Microlyte® across various care settings, including outpatient and advanced wound care.

About BioLab Holdings

BioLab Holdings, Inc. specializes in wound protection and has committed to optimizing care standards through scientifically-backed innovations. Their diverse product range includes items like Membrane Wrap - Lite™ and Membrane Wrap™, which utilize human tissue allograft from amniotic membranes for effective wound management. The company's mission remains centered around science, compassion, and community collaboration.

About Imbed Biosciences

On the other hand, Imbed Biosciences focuses on advancing wound care technologies through its SAM™ Antimicrobial Technology. Their platform integrates multiple therapeutic agents into ultra-thin, biocompatible matrices aimed at significantly reducing infection risks, minimizing pain, and enhancing healing across chronic and acute wounds.

In summary, the partnership between BioLab Holdings and Imbed Biosciences epitomizes a forward-thinking approach to wound care, showcasing the potential of advanced synthetic technologies in meeting varied clinical needs. This collaboration is expected to set new benchmarks for wound care outcomes, ultimately leading to improved patient care.